Journal of Controlled Release

Stubborn cancer tumors were completely (and safely) eliminated in a mouse model with a small but mighty treatment method using nanoparticles, controlled drug release in stages, and light from lasers.

The high recurrence rate of bladder cancer is often attributed to inadequate tumor visualization and localization. To address this limitation, the Hotliposome group at National Taiwan University has developed a mucoadhesive nanoplatform, HMSN(E)-SH, which selectively targets tumor tissue and enhances imaging precision, supporting the advancement of non-invasive diagnostic strategies.

Regenerative therapy to treat heart failure is more effective when the mitochondria of the regenerative cells are activated prior to treatment.

Researchers develop new method suppressing the distribution of drugs to healthy tissues, but also to rapidly removes the drugs once distributed in the body, which could improve the accuracy of imaging diagnosis of difficult cancers, reduce toxicity to healthy tissues, and furthermore improve the effectiveness of treatment.

Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein.

A research group at Osaka Metropolitan University has developed a drug delivery system that activates a strong cellular immune response to attack cancer cells, using one-tenth of the amount of antigen needed in the group’s previous work. By incorporating positively charged cationic lipids into liposomes and adding negatively charged pH-responsive polysaccharides to the surface, the research group increased the uptake efficiency of liposomes encapsulating cancer antigens by dendritic cells by approximately five times, which increased cytokine production by about 100 times. This increased M1-type macrophages, which activate cancer immunity, and decreased M2-type macrophages, which promote cancer growth.